Navigation Links
Pharsight Launches PK Accelerator(TM)
Date:6/24/2008

PK Accelerator Bundled Solution Accelerates Pharmacokinetic Analysis and

Reporting

MOUNTAIN VIEW, Calif., June 24 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it will be launching PK Accelerator (PKA(TM)), a system of bundled software coupled with a rapid deployment service provided at a fixed price and fixed scope. Adopting PK Accelerator will allow small to mid-sized organizations to deploy Pharsight's "best practices" solution for end-to-end pharmacokinetic analysis and validatable CFR 21 part 11 reporting in as little as 90 days.

Small to mid-sized research oriented pharmaceutical and biotech companies deploying PK Accelerator will be able to take advantage of the operational efficiencies Pharsight's enterprise and desktop software packages were designed to deliver. The software components of the PKA bundle will consist of the Pharsight(R) Knowledgebase Server(TM) (PKS), WinNonlin(R) Autopilot(TM), PKS Reporter(TM), the PKS and WinNonlin Validation Suites(TM), upgrades to WinNonlin Enterprise, and a choice of two of the following database connectors: Watson(TM), Excel(TM), or CDISC. All of these components have been designed for seamless interoperability and will be implemented as a complete system with minimal configuration. PK Accelerator will bring state-of-the-art clinical pharmacology archiving, analysis, and reporting capabilities within reach of smaller firms by standardizing the system's training and deployment procedures and leveraging Pharsight's best practices recommendations for system configuration and implementation.
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference
2. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
3. Pharsight Hosts European PKS User Meeting
4. Pharsight Achieves $7.6 Million In Quarterly Revenue
5. Pharsight Signs Two New DMX(R) License Customers
6. Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
7. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
8. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
9. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
10. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
11. Pharsight Achieves $7.4 Million in Quarterly Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
(Date:11/22/2014)...  The element of surprise has been a major ... without warning. Until now, epidemiologists had nothing to measure ... resulting in suboptimal responses to both the H1N1 pandemic ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 That ... virus gene structural changes have been found that invariably ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... 1 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), ... developing novel medicines in the areas of hepatitis ... the third quarter ended,September 30, 2007 and operational ... an important transition for Anadys,",said Steve Worland, Ph.D., ...
... Growth of 58.9% Year-over-Year, SHENZHEN, China, Nov. ... MR ), a leading developer, manufacturer,and marketer of ... presence, today announced its selected unaudited financial,results for ... Highlights for Third Quarter 2007, -- Third ...
... Healthcare (Nasdaq: MRGE ; TSX: MRG), today,announced that ... Qualifications Panel stating that the panel determined to continue,the ... Stock Market,subject to the Company,s filing of its Form ... later than January 29, 2008. As indicated in the ...
Cached Biology Technology:Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9Mindray Medical International Announces Third Quarter 2007 Results 2Mindray Medical International Announces Third Quarter 2007 Results 3Mindray Medical International Announces Third Quarter 2007 Results 4Mindray Medical International Announces Third Quarter 2007 Results 5Mindray Medical International Announces Third Quarter 2007 Results 6Mindray Medical International Announces Third Quarter 2007 Results 7Mindray Medical International Announces Third Quarter 2007 Results 8Mindray Medical International Announces Third Quarter 2007 Results 9Mindray Medical International Announces Third Quarter 2007 Results 10Mindray Medical International Announces Third Quarter 2007 Results 11Mindray Medical International Announces Third Quarter 2007 Results 12Mindray Medical International Announces Third Quarter 2007 Results 13Mindray Medical International Announces Third Quarter 2007 Results 14Mindray Medical International Announces Third Quarter 2007 Results 15Mindray Medical International Announces Third Quarter 2007 Results 16Mindray Medical International Announces Third Quarter 2007 Results 17Mindray Medical International Announces Third Quarter 2007 Results 18Mindray Medical International Announces Third Quarter 2007 Results 19Mindray Medical International Announces Third Quarter 2007 Results 20NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 2NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 3
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... developed a computer modeling method to accurately predict how ... the complex work from an inhibitory weeks-long process to ... efficient evaluation of a nerve,s response to millions of ... accurate and capable electrodes to stimulate nerves and thereby ...
... MD, a clinician and scientific investigator in the Division ... Beth Israel Deaconess Medical Center (BIDMC) has been selected ... the Doris Duke Charitable Foundation. The three-year award, which ... and environmental factors that lead to kidney disease in ...
... its first appearance in Texas, a prehistoric crocodile thought to ... native of the Lone Star State. The switch in ... the identification of a well-preserved, narrow fossil snout that was ... The 96-million-year-old fossil from Texas is the oldest prehistoric crocodile ...
Cached Biology News:Fast prediction of axon behavior 2BIDMC scientist David J. Friedman, M.D., receives award from Doris Duke Charitable Foundation 296-million-year-old fossil suggests prehistoric crocodile Terminonaris was Texas native 296-million-year-old fossil suggests prehistoric crocodile Terminonaris was Texas native 396-million-year-old fossil suggests prehistoric crocodile Terminonaris was Texas native 4
... tissue array is designed for rapidly ... in extensive panels of different types ... kidney, liver, lung, muscle, spleen and ... charged glass slide. Each tissue ...
... ml. Improves reproducibility and quality ... streaking.Eliminates extra spots caused by ... throughout entire 2-D runs, ensuring ... for both analytical and preparative ...
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
...
Biology Products: